雷特格韦在挽救性治疗失败患者中的单中心队列研究经验。 - Suppr | 超能文献

A single-center cohort experience of raltegravir in salvage patients failing therapy.

作者信息

Teague Alastair, Scott Chris, Bower Mark, Gazzard Brain, Nelson Mark, Stebbing Justin

出版信息

J Acquir Immune Defic Syndr. 2010 Apr;53(5):666-7. doi: 10.1097/QAI.0b013e3181ba4845.

DOI:10.1097/QAI.0b013e3181ba4845

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

A single-center cohort experience of raltegravir in salvage patients failing therapy.雷特格韦在挽救性治疗失败患者中的单中心队列研究经验。

J Acquir Immune Defic Syndr. 2010 Apr;53(5):666-7. doi: 10.1097/QAI.0b013e3181ba4845.

2

Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.

AIDS. 2011 Nov 28;25(18):2306-8. doi: 10.1097/QAD.0b013e32834cdb89.

3

Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.达芦那韦-依曲韦林-雷特格韦作为挽救性联合疗法用于一名接受过大量治疗的HIV感染患者。

AIDS Patient Care STDS. 2008 Nov;22(11):841-2. doi: 10.1089/apc.2008.0051.

4

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.监测巴西里约热内卢接受拉替拉韦挽救治疗的 HIV-1 感染患者中耐药突变的出现：一项随访研究。

J Med Virol. 2012 Dec;84(12):1869-75. doi: 10.1002/jmv.23409.

5

Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.

AIDS Patient Care STDS. 2008 May;22(5):355-7. doi: 10.1089/apc.2007.0215.

6

Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.一种新型挽救疗法用于R5嗜性HIV感染患者的耐用性和安全性：马拉维若、雷特格韦、依曲韦林。

J Acquir Immune Defic Syndr. 2011 Apr;56(4):e113-5. doi: 10.1097/QAI.0b013e31820a9ae4.

7

Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.新型抗逆转录病毒药物在挽救治疗方案中的应用：一例对拉替拉韦早期病毒学失败的病例

Scand J Infect Dis. 2010 Mar;42(3):237-9. doi: 10.3109/00365540903447018.

8

High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.拉替拉韦治疗失败的患者中出现较高频率的多替拉韦耐药。

J Antimicrob Chemother. 2015 Mar;70(3):926-9. doi: 10.1093/jac/dku439. Epub 2014 Nov 10.

9

Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.基于拉替拉韦的挽救治疗在 HIV-1 感染、治疗经验丰富患者中的四年数据：SALIR-E 研究。

Int J Antimicrob Agents. 2014 Feb;43(2):189-94. doi: 10.1016/j.ijantimicag.2013.10.013. Epub 2013 Nov 15.

10

Dynamics of HIV DNA and residual viremia in patients treated with a raltegravir-containing regimen.接受含拉替拉韦方案治疗的患者中HIV DNA和残余病毒血症的动态变化

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):e18-20. doi: 10.1097/QAI.0000000000000414.

引用本文的文献

1

Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study.在HIV门诊研究中，接受过抗逆转录病毒治疗的参与者使用含雷特格韦方案后的长期免疫和病毒学反应。

HIV Clin Trials. 2015 Aug;16(4):139-46. doi: 10.1179/1528433614Z.0000000019. Epub 2015 Jul 1.

2

96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.拉替拉韦联合优化背景方案挽救治疗 HIV 感染者的 96 周随访：一项意大利多中心经验。

PLoS One. 2012;7(7):e39222. doi: 10.1371/journal.pone.0039222. Epub 2012 Jul 11.